News & Events

• May 25, 2021
  

  C-Path Virtual Workshop to Feature Latest Advances in Clinical Trials for T1D

  More than 300 Attendees and 20 Speakers Are Expected to Participate in the International Workshop, June 15-16

  TUCSON, Ariz., May 25, 2021 — Critical Path Institute (C-Path) today announced its schedule for the Design of Clinical Trials in New-Onset Type 1 Diabetes: Regulatory Considerations for Drug Development Workshop, to be held virtually June 15-16. Together with the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and in collaboration with Benaroya Research Institute, INNODIA and JDRF, this 2-day public workshop will focus on the implementation of endpoints and outcome measures for clinical trials in new onset type 1 diabetes (T1D). More than 300 researchers, pharmaceutical representatives, academia members, investigators, T1D patients and regulatory experts from throughout the United States and Europe are expected to gather virtually to hear 15 presentations about T1D research and medical product development.

• May 19, 2021
  

  C-Path Welcomes Alphabet Clinical Policy and Strategy Head, Former FDA Commissioner to Board

  TUCSON, Ariz., May 19, 2021 — Critical Path Institute today announced the appointment of Robert M. Califf, MD, MACC, head of Clinical Policy and Strategy for Google parent company Alphabet’s Verily Life Sciences and Google Health divisions, to C-Path’s Board of Directors. Califf served as the U.S. Food and Drug Administration (FDA) Commissioner under President Barack Obama’s administration from 2016-2017.

• May 19, 2021
  

  ERA4TB Update

  NEWSLETTER: The ERA4TB (European Regimen Accelerator for Tuberculosis) project, a public-private initiative devoted to accelerating the development of new treatment regimens for tuberculosis, issued its first newsletter this month which includes updates on the project thus far. Read the full communication and subscribe, here: https://era4tb.org/newsletter.

• May 18, 2021
  

  C-Path Request for Proposal for External Communications

  Critical Path Institute (C-Path) is seeking a proposal, including timelines and budget, for external marketing, communications, public relations and related services. C-Path Request for Proposal for External Communications
• May 12, 2021
  

  C-Path Announces Accelerated Data Sharing Collaboration with Tufts Medical Center

  FDA Grant Supports Use of Real-World Data to Generate Real-World Evidence in Neonates

  TUCSON, Ariz., May 12, 2021 — Critical Path Institute (C-Path) and Tufts Medical Center have announced a joint venture to integrate the first patient-level clinical trial data to generate actionable real-world evidence (RWE) for neonatal drug development, from real-world neonate data (RWD). This activity, funded by a grant from the U.S. Food and Drug Administration (FDA), is being executed through a neonatal pilot project within C-Path’s International Neonatal Consortium (INC). The data sharing collaboration and transfer also marks the fastest on record for C-Path — starting with the Data Contribution Agreement negotiations and receipt of the data in three months’ time this March.